Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06554795 · ClinicalTrials.gov registry record · Phase 1
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
A Phase 1 study of Solid Tumor, Adult, sponsored by DualityBio.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 360
- Enrollment target
- 20
- Study locations
NCT06554795 is a Phase 1 study of Solid Tumor, Adult that is actively recruiting participants, run by DualityBio. The registered enrollment target is 360 participants, above the 186-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (94% higher). The trial reports 20 study locations across 16 states.
The verdict
NCT06554795, a Phase 1 study of Solid Tumor, Adult, is actively recruiting participants, sponsored by DualityBio.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 360 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 1/2a First-in-Human Study of DB-1419 in Advanced/Metastatic Solid Tumors
Conditions Studied
Interventions
- DRUG DB-1419
Study Locations (20)
California
- Site USA12-0 - Los Angeles
- Site USA08-0 - Newport Beach
- Site USA13-0 - Sacramento
New South Wales
- AUS03-0 - North Ryde
- AUS01-0 - Randwick
Anhui
- Site CHN24-0 - Hefei
- Site CHN39-0 - Hefei
District of Columbia
- Site USA06-0 - Washington D.C.
Florida
- Site USA02-0 - Florida City
Illinois
- Site USA11-0 - Chicago
North Carolina
- Site USA03 - Huntersville
Pennsylvania
- Site USA05-0 - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 360 participants |
| Start Date | 2024-09-03 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06554795
The ClinicalTrials.gov registry entry for NCT06554795 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 360 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 186-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target (94% higher). The listed sponsor is DualityBio, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Solid Tumor, Adult appearing as the primary indexed condition, and to 1 intervention - of which DB-1419 is the first listed.
NCT06554795 reports 20 study locations spanning 16 distinct geographic areas - top geographies include California, New South Wales, Anhui.
Frequently Asked Questions
What is clinical trial NCT06554795 about?
NCT06554795 is a clinical study titled "First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors". A Phase 1/2a First-in-Human Study of DB-1419 in Advanced/Metastatic Solid Tumors
What is the current status of trial NCT06554795?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 360 participants. The study started on 2024-09-03. Estimated completion is 2027-02.
What conditions does trial NCT06554795 study?
This clinical trial studies the following conditions: Solid Tumor, Adult.
What interventions are being tested in trial NCT06554795?
The interventions under investigation include: DB-1419 (DRUG).
Who is sponsoring clinical trial NCT06554795?
This trial is sponsored by DualityBio, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06554795 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Illinois, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.